B

BeOne

Global oncology therapeutics discovery, development, manufacturing

Vice President - Global Product Team Leader, Lung Cancer

Full-TimePosted on 10/15/2026
$312k - $402k/yr
Expert
Bachelor's
Remote in USA
Remote
Biology & Biotech

About the job

Requirements
  • Advanced degree and 10+ years in drug development, product strategy, and global commercialization, including leading cross-functional teams.
  • Demonstrated clinical research expertise in oncology; direct expertise in lung cancer disease is preferred.
  • Experience in drug development and global commercialization across the product lifecycle.
  • Business acumen, including understanding unmet market needs, developing product strategies, creating a clear path to win, and driving innovation through global commercialization of assets.
  • Ability to think at the enterprise level, sense the system, and solve problems.
  • A record of engaging senior leadership and driving business outcomes in multidisciplinary teams.
  • Ability to make decisions that positively impact the business.
  • Strategic leadership skills, including strategic, analytical, and innovative thinking and the ability to analyze and solve complex challenges quickly and creatively; proven experience as a decisive leader in a strategic multifunctional environment.
  • Experience with global regulatory submissions and interactions with major health authorities; NDA and/or BLA submission experience is strongly desired.
  • Ability to communicate effectively at multiple levels of the organization.
  • Ability to work effectively in a global, cross-functional matrix organization and across diverse cultures.
  • Ability to communicate flexibly and effectively in leadership settings.
Responsibilities
  • Own the asset strategy from proof of concept through global product launch and lifecycle management, aligned with disease-area and portfolio strategy.
  • Lead the Global Product Team, responsible for establishing, driving, and executing global strategy for a single asset throughout its lifecycle, from early clinical development through late-stage pivotal studies, commercial launch, market access, post-marketing commitments, asset growth, and patent expiration.
  • Lead integrated molecule strategy throughout the product lifecycle to maximize value for the company and healthcare ecosystem.
  • Build and lead a high-performing Global Product Team, advocate for appropriate resourcing, and ensure alignment across relevant functions to deliver the program vision and strategy.
  • Advocate for the asset at the enterprise level in alignment with business priorities.
  • Ensure cross-functional strategic input is incorporated into clinical development plans and regulatory strategy, including trial design, endpoints, appropriate comparators, Target Product Profile, and regulatory pathway, to support commercial success and global market access.
  • Act as a role model and ambassador for internal and external stakeholder engagement in strategy development, communicating the molecule's scientific story and differentiation.
  • Collaborate with the Global Product Team and key internal stakeholders to develop and deliver the product Target Product Profile.
  • Lead integrated product development and commercialization plans aligned with business objectives and differentiated from competition.
  • Communicate development strategy at governance meetings to secure funding and endorsement.
  • Hold self and the team accountable for delivering governance-approved business cases in collaboration with the global commercial franchise leader and functional management.
  • Manage and mitigate risks, communicate them, and present potential mitigation strategies to senior leadership.
  • Work with global and regional commercial teams to develop, evaluate, and deliver commercial strategies and plans; define lifecycle-management investment options and business cases, recommend investments, and maximize brand portfolio value.
  • Provide leadership support to multidisciplinary subteams whose work supports the Global Product Team and product strategy.
  • Partner with the Global Program Manager to translate goals and strategy into actionable plans, execute within established guardrails, proactively manage risks and issues, and drive team effectiveness and alignment with governance processes.
  • Maintain team effectiveness through collaboration, influence, coaching, and mentoring of cross-functional team members.
  • Partner with other Global Product Teams to develop disease-area or franchise-wide strategies and maximize synergies with company assets.
  • Partner with Investor Relations and Corporate Communications to develop and manage external messages for the analyst community in collaboration with the clinical development lead.
  • Collaborate with Business Development and relevant functions in discussions with external partners to maximize lifecycle opportunities.
  • Ensure appropriate governance and compliance and protect company rights, data, and intellectual property.
Desired Qualifications
  • Direct expertise in lung cancer disease.
  • NDA and/or BLA submission experience.

About the company

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Get referred to BeOne

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 25, 2026 FDA approval expanded TEVIMBRA in first-line HER2-positive gastroesophageal cancer.
  • August 31, 2026 Phase 3 survival data strengthened ZIIHERA-containing regimens.
  • Q2 2026 revenue hit $1.7 billion; management raised 2026 guidance to $6.8 billion.

What critics are saying

  • BeOne accepted developed-market pricing parity and Medicaid rebates on future U.S. approvals.
  • Zydus' BRUKINSA ANDA lawsuit targets patents; a 2034 composition patent remains the fortress.
  • AbbVie's trade-secrets case over BGB-16673 still threatens the BTK-degrader franchise.

What makes BeOne unique

  • BeOne built 35-plus assets and 93 trials across 1,100 U.S. sites by September 2026.
  • BRUKINSA dominates revenue, with 2026 global sales above $1.2 billion quarterly.
  • Hopewell, New Jersey gives BeOne U.S. manufacturing, R&D, and packaging capacity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • 401(k) Retirement Plan
  • Wellness Program
  • Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

8%

1 year growth

-6%

2 year growth

-1%
Associated Press
Oct 6th, 2026
Onco360 partners with BeOne Medicines to distribute Beqalzi for relapsed mantle cell lymphoma

Onco360, an independent specialty pharmacy, has been selected as a pharmacy partner by BeOne Medicines for Beqalzi (sonrotoclax). The drug is indicated for treating adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor. Beqalzi is a BCL-2 protein inhibitor. In a Phase 1/2 study of 103 adult patients with relapsed/refractory mantle cell lymphoma, the drug achieved an overall response rate of 52.4%, with a median time to response of 1.9 months. The median duration of response was 15.8 months. Onco360 is headquartered in Louisville, Kentucky, and operates as a flagship brand of PharMerica Corporation.

Yahoo Finance
Sep 4th, 2026
BeOne secures US pharma-tariff exemption after $1B+ manufacturing investment, but pricing concessions raise margin concerns

BeOne Medicines secured an exemption from Section 232 pharmaceutical tariffs through a voluntary agreement with the US government. The deal recognises over $1 billion in US manufacturing investment, including a $300 million expansion in Hopewell, New Jersey. The exemption protects BeOne from import duties on patented pharmaceuticals and ingredients. However, the company committed to pricing future FDA-approved medicines in line with other developed markets and participating in the Medicaid GENEROUS Model, which uses supplemental rebates. The Hopewell expansion will add small-molecule manufacturing and packaging capacity, creating approximately 120 full-time jobs. The facility will support a portfolio of more than 35 assets. Whilst the tariff exemption reduces supply-chain risk, international reference pricing commitments could limit pricing flexibility for future oncology medicines. Neither the tariff savings nor the financial impact of pricing concessions was disclosed.

Yahoo Finance
Aug 13th, 2026
Revolution Medicines shares rise 6.2% on BeOne-funded Phase 3 RAS(ON) deal

Revolution Medicines has partnered with BeOne Medicines in a multi-part collaboration combining BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors. The August 2026 deal grants BeOne exclusive development and commercialisation rights in select Asian markets and commits BeOne to fund a global Phase 3 trial. Revolution Medicines reported a net loss of $644.37 million in Q2 2026 and $1.1 billion over six months. The company currently generates no revenue but projects $2.3 billion in revenue and $402.5 million in earnings by 2029. The partnership shifts near-term risk by offloading Phase 3 costs whilst providing access to milestone and royalty potential. However, the core investment case remains unchanged: regulatory progress and commercialisation of daraxonrasib, with trial execution and spending presenting the biggest risks.

Yahoo Finance
Aug 5th, 2026
BeOne Medicines Q2 revenue up 30% to $1.7B as BRUKINSA sales top $1.2B globally

BeOne Medicines reported second-quarter revenue of $1.7 billion, up 30% year over year, with GAAP earnings per ADS rising 144% to $2.05. The company's BTK inhibitor BRUKINSA generated more than $1.2 billion in global sales, increasing 31% from the prior year. The company raised its 2026 revenue guidance to CNY 6.6 billion–CNY 6.8 billion and expects GAAP operating income of CNY 1 billion–CNY 1.1 billion. Free cash flow doubled year over year to CNY 435 million. BeOne received FDA approval for Beqalzi in relapsed or refractory mantle cell lymphoma and reported positive Phase III results for a chemotherapy-free BRUKINSA regimen. US BRUKINSA sales totalled $893 million, up 31%, driven by demand in chronic lymphocytic leukaemia and non-CLL indications.

Yahoo Finance
Jul 23rd, 2026
BeOne CEO sells $34.6M in stock while retaining 50M+ shares

John Oyler, chief executive officer of BeOne Medicines AG, sold 109,713 American Depositary Shares worth $34.6 million on 20 and 21 July 2026, according to SEC filings. The transactions were executed under a Rule 10b5-1 trading plan adopted in March 2026. Despite the sale, Oyler retains a substantial ownership position exceeding 50.4 million total shares through various holdings. These include 28.2 million shares held through Oyler Investment LLC and 9.5 million shares in a Roth IRA account. The shares were sold at a weighted average price of $315.28. BeOne Medicines is a commercial-stage oncology biopharmaceutical company with $5.7 billion in trailing twelve-month revenue and a market capitalisation of $34.2 billion.